Share this video  

VJHemOnc is committed to improving our service to you

ASH 2018 | CLL news from ASH 2018: ibrutinib strikes again!

Stephan Stilgenbauer
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Bendamustine Ibrutinib Obinutuzumab Rituximab Venetoclax
ALLIANCE A041202 ECOG-E1912 iLLUMINATE MURANO

Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the chronic lymphocytic leukemia (CLL) highlights at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Stephan Stilgenbauer

1:17
Still a role for chemoimmunotherapy in CLL: GREEN results
Stephan Stilgenbauer • 7 Dec 2019
2:52
Importance of Bcl-2-targeted therapies
John Gribben et al. • 4 Dec 2015
1:06
What should we be focusing on in CLL research?
Stephan Stilgenbauer
1:26
The 20th anniversary of the German CLL Study Group and the importance of collaboration
Stephan Stilgenbauer • 16 Sep 2016

Related Videos

1:41
Key challenges of using the intestinal microbiome as a biomarker
Melody Smith
1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
1:44
The future of AML therapy
Andreas Burchert
0:42
Treating pediatric patients with hematological malignancies
Claudia Rössig
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals